{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:30:26Z","timestamp":1790868626057,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.lungcan.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T16:27:46Z","timestamp":1644337666000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer"],"prefix":"10.1016","volume":"166","author":[{"given":"Kristin Toftaker","family":"Killingberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarje Ons\u00f8ien","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Fl\u00f8tten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd Terje","family":"Brustugun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo W.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti","family":"Hornslien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfaye","family":"Madebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Schytte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Risum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsakonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Engleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Henning","family":"Gr\u00f8nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9804","key":"10.1016\/j.lungcan.2022.02.002_b0005","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.lungcan.2022.02.002_b0010","doi-asserted-by":"crossref","unstructured":"G.P. Kalemkerian, B.W. Loo, W. Akerley, A. Attia, M. Bassetti, Y. Boumber, et al., NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J. Natl. Compr. Canc. Netw. 2018;16(10):1171-82, doi: 10.6004\/jnccn.2018.0079.","DOI":"10.6004\/jnccn.2018.0079"},{"issue":"34","key":"10.1016\/j.lungcan.2022.02.002_b0015","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.02.002_b0020","doi-asserted-by":"crossref","unstructured":"K.A. Higgins, S. Gorgens, L.J. Sudmeier, C. Faivre-Finn, Recent developments in limited stage small cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 2):S147-S52, 10.21037\/tlcr.2019.05.13.","DOI":"10.21037\/tlcr.2019.05.13"},{"issue":"4","key":"10.1016\/j.lungcan.2022.02.002_b0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2022.02.002_b0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.02.002_b0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gr\u00f8nberg","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.002_b0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/0284186X.2015.1092584","article-title":"Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer","volume":"55","author":"Gronberg","year":"2016","journal-title":"Acta Oncol. (Stockholm, Sweden)."},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.002_b0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ijrobp.2021.05.003","article-title":"<oderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: a multicenter, phase II, randomized trial","volume":"111","author":"Qiu","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"15","key":"10.1016\/j.lungcan.2022.02.002_b0050","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2021.39.15_suppl.8505","article-title":"Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)\/RTOG 0538","volume":"39","author":"Bogart","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2022.02.002_b0055","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2022.02.002_b0060","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Supportive Care in Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2022.02.002_b0065","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1097\/JTO.0000000000000672","article-title":"Utilization of hyperfractionated radiation in small-cell lung cancer and its impact on survival","volume":"10","author":"Schreiber","year":"2015","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2022.02.002_b0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2019.08.007","article-title":"Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey","volume":"136","author":"Levy","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.002_b0075","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/S1470-2045(13)70493-5","article-title":"Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials","volume":"15","author":"Zikos","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.002_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.002_b0085","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30a","author":"Bergman","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"#cr-split#-10.1016\/j.lungcan.2022.02.002_b0090.1","unstructured":"P.M. Fayers, K. Bjordal, M. Groenvold, D. Curran, A. Bottomley, on, Group botEQoL. The EORTC QLQ-C30 Scoring Manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels 2001.: 2001"},{"key":"#cr-split#-10.1016\/j.lungcan.2022.02.002_b0090.2","unstructured":"2001 [cited 2021. Available from: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf."},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.002_b0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2022.02.002_b0100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual. Life Res."},{"issue":"11","key":"10.1016\/j.lungcan.2022.02.002_b0105","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00520-010-1016-5","article-title":"Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Supportive Care in Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.002_b0110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2009.04.075","article-title":"Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study","volume":"77","author":"van Loon","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.002_b0115","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.ijrobp.2010.12.072","article-title":"Positron emission tomography\/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer","volume":"82","author":"Shirvani","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2022.02.002_b0120","doi-asserted-by":"crossref","unstructured":"M.J. Farrell, J.B. Yahya, C. Degnin, Y. Chen, J.M. Holland, M.A. Henderson, et al. Elective Nodal Irradiation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns. Clinical lung cancer. 2020;21(5):443-9 e4, 10.1016\/j.cllc.2020.02.020.","DOI":"10.1016\/j.cllc.2020.02.020"},{"key":"10.1016\/j.lungcan.2022.02.002_b0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2019.10.022","article-title":"Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018","volume":"139","author":"Reale","year":"2020","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.002_b0130","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/annonc\/mdv065","article-title":"Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial\u2020","volume":"26","author":"Pujol","year":"2015","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2022.02.002_b0135","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2013.53.5153","article-title":"Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509","volume":"32","author":"Satouchi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.02.002_b0140","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fphar.2017.00339","article-title":"The humanistic burden of Small Cell Lung Cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature","volume":"8","author":"Bennett","year":"2017","journal-title":"Front Pharmacol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.02.002_b0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2022.02.002_b0150","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1740774516655101","article-title":"Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992)","volume":"13","author":"Atherton","year":"2016","journal-title":"Clin. Trials"},{"issue":"1s","key":"10.1016\/j.lungcan.2022.02.002_b0155","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.chest.2020.03.007","article-title":"Considerations for reporting and reviewing studies including health-related quality of life","volume":"158","author":"Lapin","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.002_b0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cllc.2018.08.015","article-title":"Radiation dose and fractionation for limited-stage small-cell lung cancer: survey of US radiation oncologists on practice patterns","volume":"20","author":"Farrell","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2022.02.002_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122895","article-title":"A comparison of hypofractionated and twice-daily thoracic irradiation in limited-stage small-cell lung cancer: an overlap-weighted analysis","volume":"13","author":"Yan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.002_b0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1634\/theoncologist.2017-0263","article-title":"A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention","volume":"23","author":"Dunnill","year":"2018","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.lungcan.2022.02.002_b0175","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.002_b0180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cllc.2017.02.008","article-title":"Emotional problems, quality of life, and symptom burden in patients with lung cancer","volume":"18","author":"Morrison","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.02.002_b0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2016.10.003","article-title":"Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer","volume":"102","author":"Halvorsen","year":"2016","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.002_b0190","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdq576","article-title":"Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003\u201308004, RTOG 0212 and IFCT 99\u201301)","volume":"22","author":"Le P\u00e9choux","year":"2011","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.02.002_b0195","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2010.29.6053","article-title":"Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis","volume":"29","author":"Sun","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2022.02.002_b0200","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJM199908123410703","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group","volume":"341","author":"Auperin","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.002_b0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.radonc.2016.11.012","article-title":"Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: do all patients benefit?","volume":"122","author":"Farooqi","year":"2017","journal-title":"Radiotherapy Oncol."},{"issue":"30","key":"10.1016\/j.lungcan.2022.02.002_b0210","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2012.43.0116","article-title":"Cancer- and cancer treatment-associated cognitive change: an update on the state of the science","volume":"30","author":"Ahles","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.02.002_b0215","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.23222","article-title":"Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation","volume":"112","author":"Grosshans","year":"2008","journal-title":"Cancer"},{"issue":"3 Suppl","key":"10.1016\/j.lungcan.2022.02.002_b0220","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.ijrobp.2009.05.070","article-title":"Radiation dose-volume effects in the esophagus","volume":"76","author":"Werner-Wasik","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:59:51Z","timestamp":1759237191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":45,"alternative-id":["S0169500222000423"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.02.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}